6 research outputs found

    Expérience précoce de la réponse à la pandémie à Syndrome Respiratoire Aigu Sévère à Corona Virus SARS-COV 2 appelé aussi Corona Virus Disease 19 (COVID-19) aux Cliniques Universitaires de Kinshasa: Early experience of response to Severe Acute Respiratory Syndrome-Coranovirus-2 (SARS-COV-2) pandemic at Kinshasa university hospital

    Get PDF
    The Democratic Republic of Congo (DRC) declared the first case of Coronavirus infection disease (COVID-19) on March 10, 2020. Ever since then, assessment in terms of management and care outcomes for COVID-19 patients has not yet been formally established. Since, the number of patients has been increasing; however, there has been no formal guideline for COVID-19 patient management. This paper provides an overview of the experience of the overall management of COVID-19 at the Kinshasa University Hospital (KUH), between March and the end of April 2020. Clinical data of 49 patients from surronding municipalities, including 61% of males, are presented in this report. Patients were young (median age 34 years). At admission, 20.4% of patients were at advanced stage and 6.1% at severe stage, and almost all of them have been using self-medication prior to admission at the hospital. The lethality rate was 10.2%. In almost all the cases (8 cases out of 10), death occurred within the first 24 hours following the admission. The response to COVID-19 was set up after a few twists and turns. With the support of a few partners and the government, we are seeing an improvement in the management of COVID-19 at the KUH. Delayed referral, self-medication and stigma are among the factors that influenced the disease severity and contributed to the high mortaly we have observed. La République démocratique du Congo (RDC) a déclaré le premier cas de la maladie à Coronavirus (COVID-19) le 10 mars 2020. Depuis lors, l’évaluation de la prise en charge et de l’issue vitale des patients suivis n’ont pas encore été formellement rapportées. Le présent article donne un aperçu de l’expérience de la prise en charge globale de la COVID-19 aux Cliniques Universitaires de Kinshasa, entre mars et fin avril 2020. Quarante-neuf (âge médian 34 ans, sexe masculin 61%, habitant les communes environnantes) ont été inclus. Près d’un tiers des patients étaient admis aux stades critiques (20,4%) ou sévère (6,1%) recourant souvent à l’automédication. Le taux de létalité a été 10,2% des cas. Le décès était survenu endéans les 24 premières heures dans la quasi-totalité des cas (8 cas/10 patients). Les patients sont très jeunes. La riposte à la pandémie a été d’installation lente, renforcée progressivement par l’appui des partenaires traditionnels et du gouvernement central. L’impact de ces interventions a contribué à une amélioration de la prise en charge de la COVID-19 aux CUK. La référence tardive, mais aussi l’autoprise en charge à domicile, corollaires à la stigmatisation communautaire seraient une explication plausible au nombre élévé de décès enregistrés dans cette institution

    Tests diagnostiques de l’infection à Coronavirus (COVID-19) : des atouts et des limites: Diagnosis testing for Coronavirus infection disease (COVID 19): Assets and limits

    Get PDF
    The world is going through a serious health crisis due to the COVID 19 pandemic. Although little is known about COVID-19, we have observed an increased interhuman transmission of etiological agent SARS-Cov-2 and we assume that each new cases of COVID-19 get at least two or three news persons infected. Therefore, the test for detection of the infection should be much implemented as an efficient strategy to fight against the COVID 19 pandemic. The COVID-19 diagnostic tests are an essential tool for assessing the pandemic. This review paper will discuss the advantages and limitations of the diagnosis tests for COVID 19. There are 2 categories of tests: those that directly detect the virus or its component, and those that search for the antibodies generated by the virus infection. The real time Reverse transcriptase Polymerase chain reaction (test rt-RT-PCR) remains the gold standard for the diagnosis of COVID-19. Its sensitivity on the nasopharynx swab seems high, though false negative cases can occur, with an average of 30% of cases. Serological test detect specific antibodies against SARS-COV-2. They help identify individuals that have been infected by the virus, those healed and that have acquired immunity against the virus. They are diagnosis orientation tests of COVID-19. Until now, none of these tests are 100% reliable, but they are used by a qualified collaborating medical staff. They can help identify the majority of the infected and immunized individuals. Le monde entier fait face Ă  une crise sanitaire sans prĂ©cĂ©dent due Ă  la pandĂ©mie de maladie Ă  virus SARS-COV-2 alias COVID-19. MalgrĂ© les connaissances très incomplètes sur la COVID-19, on a constatĂ© une contagiositĂ© interhumaine Ă©levĂ©e au dĂ©but de la pandĂ©mie actuelle, et on estime que chaque nouveau cas de COVID-19 infecte en moyenne deux Ă  trois personnes. En consĂ©quence, la stratĂ©gie de lutte contre la pandĂ©mie Ă  COVID-19 qui Ă©branle nos sociĂ©tĂ©s passe nĂ©cessairement par une intensification des tests de dĂ©tection de l’infection. Ces tests diagnostiques de la COVID-19 sont un outil essentiel pour suivre la propagation de la pandĂ©mie. Ainsi, l’objectif de la prĂ©sente revue de la littĂ©rature est d’aborder le diagnostic de l’infection Ă  Coronavirus (COVID-19) en s’attardant sur les tests de diagnostic, leurs atouts et leurs limites. Il y a deux catĂ©gories de test : ceux qui recherchent la prĂ©sence directe du virus ou de ses fragments, et ceux qui recherchent les anticorps rĂ©sultant de l’infection par le virus du COVID-19. Le test real time –Reverse Transcriptase –Polymerase chain reaction (rt-RT-PCR) reste le gold standard pour le diagnostic de la COVID-19. Sa sensibilitĂ© sur les Ă©couvillons nasopharyngĂ©s semble Ă©levĂ©e, mais des faux nĂ©gatifs peuvent se produire, avec une frĂ©quence incertaine (environ 30% des cas). Les tests sĂ©rologiques dĂ©tectent les anticorps spĂ©cifiques du SARS-CoV-2. Ils permettent l’identification des individus qui ont Ă©tĂ© infectĂ©s par le virus, se sont rĂ©tablis, et ont dĂ©veloppĂ©, en thĂ©orie, une rĂ©ponse immunitaire efficace contre le virus. Ils constituent des tests d’orientation diagnostique de la COVID-19. A ce jour, aucun de ces tests n’est fiable Ă  100 %, mais, utilisĂ©s par un personnel mĂ©dical qualifiĂ© et en combinaison, ils permettent l’identification de la majoritĂ© des individus infectĂ©s et immunisĂ©s

    Surveillance des décès aux Cliniques Universitaires de Kinshasa (RDC) : la COVID-19 a-t-elle entraîné une surmortalité ? Monitoring of deaths at the Kinshasa University Hospital: has COVID-19 resulted in increase of mortality?

    Get PDF
    Context and objectives. The extent of COVID-19 impact on overall in-hospital mortality is controversial. The objectives of the study were to compare the number of deaths in the first semesters of 2018, 2019 and 2020; determine the proportion of COVID-19 cases and identify the factors associated with COVID-19 among the deaths recorded at the morgue of the Kinshasa University Hospital (KUH). Methods. We collected death certificates registered at the KUH morgue. The diagnosis of COVID-19 was confirmed using RT-PCR in all suspected subjects (from March 2020), including those who have arrived dead. Pearson’s khi-square, Student’s t-test, and logistic regression were used as statistical tests. Results. The number of deaths recorded in the first semester of 2019 (868 cases) was higher than in 2020 (768 cases) and 2018 (744 cases). In 2020, 45 deaths related to COVID-19 (6.0%) were reported. The risk of COVID-19 depended on the period (month of June 2020, OR: 5.69; p = 0.002), sex (female, 0R: 0.42; p = 0.024) and age (one additional year of age, OR: 1.02; p = 0.009). Conclusion: COVID-19 did not lead to excess intra-hospital mortality in the first semester of 2020. The proportion of the disease among deceased patients was more marked in June 2020 and the risk increased with age, especially in men. Contexte et objectifs. L’ampleur de la COVID-19 sur la mortalitĂ© intra-hospitalière globale suscite des controverses. Les objectifs de l’étude Ă©taient de comparer le nombre de dĂ©cès lors des premiers semestres de 2018, 2019 et 2020 ; dĂ©terminer la proportion des cas de COVID-19 et identifier les facteurs associĂ©s Ă  la COVID-19 parmi les dĂ©cès enregistrĂ©s Ă  la morgue des Cliniques Universitaires de Kinshasa (CUK). MĂ©thodes. Nous avons colligĂ© les certificats des dĂ©cès enregistrĂ©s Ă  la morgue des CUK. La COVID-19 a Ă©tĂ© recherchĂ©e par la RT-PCR chez tous les sujets suspects y compris les arrivĂ©s morts (Ă  partir de mars 2020). Le Khi carrĂ© de Pearson, le test t de Student et la rĂ©gression logistique ont Ă©tĂ© utilisĂ©s comme tests statistiques. RĂ©sultats. Le nombre de dĂ©cès enregistrĂ©s au premier semestre 2019 (868 cas) Ă©tait plus Ă©levĂ© qu’en 2020 (768 cas) et 2018 (744 cas). En 2020, on a rapportĂ© 45 dĂ©cès liĂ©s Ă  la COVID-19 (6,0 %). Le risque d’avoir la COVID-19 dĂ©pendait de la pĂ©riode (mois de juin 2020, OR : 5,69 ; p = 0,002), du sexe (femme, 0R : 0,42 ; p = 0,024) et de l’âge (une annĂ©e d’âge supplĂ©mentaire, OR : 1,02 ; p = 0,009). Conclusion. La COVID-19 n’a pas entraĂ®nĂ© de surmortalitĂ© intra-hospitalière au premier semestre de l’annĂ©e 2020. La proportion de la maladie parmi les patients dĂ©cĂ©dĂ©s Ă©tait plus marquĂ©e au mois de juin 2020 et le risque augmentait avec l’âge, particulièrement chez les hommes

    Human Immunodeficiency Virus Viral Load Monitoring and Rate of Virologic Suppression Among Patients Receiving Antiretroviral Therapy in Democratic Republic of the Congo, 2013-2020.

    Full text link
    peer reviewedBACKGROUND: Antiretroviral therapy (ART) expansion and viral load as a treatment monitoring approach have increased the demand for viral load testing. Many hurdles affect the coverage, quality, and use of viral load results. Estimates of viral load monitoring and viral suppression rates are needed to assess the performance of ART programs and improve human immunodeficiency virus (HIV) management outcomes. METHODS: People with HIV (PWH) viral load monitoring data were routinely collected in 84 health facilities in Kinshasa, Democratic Republic of the Congo (DRC), between 2013 and 2020. The number of PWH under ART, the number of participants with at least 1 viral load test result, the rate of viral suppression (defined as ≤1000 HIV ribonucleic acid copies per mL), and the mean turnaround time from sample collection to release of viral load test results were collected together with clinical data. RESULTS: A total of 14 057 PWH were included in the analysis. People with HIV were mainly enrolled after the "test and treat" implementation. The patients were followed for a median period of 27 months. The proportion of PWH with at least 1 available viral load largely increased in recent years. The delay from sample collection to release of viral load test results decreased overtime, from 35 days in 2018 to 16 days in 2020. Pregnancy and advanced HIV disease were associated with a lower chance of viral suppression. CONCLUSIONS: There has been considerable success in increasing viral load access for all PWH under therapy in DRC. Nevertheless, viral load testing should be intensified with a particular effort to be made in groups at higher risk of viral failure

    Epidemiological, clinical Characteristics and mortality of patients Infected with SARS-CoV-2 Admitted to Kinshasa University Hospital (KUH), the Democratic Republic of the Congo from March 24th, 2020, to January 30th, 2021: Two waves, two faces?

    Get PDF
    Context and objective: Like all epidemics, the COVID-19 pandemic occurs in several highly diverse waves. The objective of the present study was to  compare the demographic and clinical characteristics and mortality of patients between the first and second waves of COVID-19. Methods: This was a historical follow-up study conducted at the Kinshasa University Hospital (KUH) between March 2020 and January 2021. We used  the χ² test to compare proportions. Survival was described by the Kaplan Meier method. Cox regression was used to identify independent  predictors of mortality. Results: A total of 411 COVID-19 patients were enrolled. Compared to wave 1 patients, wave 2 patients were significantly  older (52.4 ±17.5 vs. 58.1 ±15.7; p=0.026). The death rate of patients in the first wave was higher than in the second wave (p=0.009). Survival was  more reduced in the first wave compared with the second wave. Predictors of mortality present in both the first and second waves were respiratory  distress and severe COVID-19 stage. Conclusion: The first wave was more lethal than the second wave with respiratory distress and severe COVID-19  stage as independent predictors in both waves. Strengthening the health system and raising awareness of preventive measures including  vaccination should continue to sustain gains.    French title: CaractĂ©ristiques Ă©pidĂ©miologiques, cliniques et mortalitĂ© des patients infectĂ©s par le SRAS-CoV-2 admis aux Cliniques Universitaires  de Kinshasa, RĂ©publique dĂ©mocratique du Congo du 24 mars 2020 au 30 janvier 2021 : Deux vagues, deux visages ? Contexte et objectif: Comme toutes les Ă©pidemies, la pandĂ©mie Ă  COVID-19 sĂ©vit en plusieurs vagues très diversifiĂ©es. L’étude a comparĂ© les  caractĂ©ristiques dĂ©mographiques et cliniques ainsi que la mortalitĂ© des patients entre la 1ère et la 2ème vague de COVID-19. MĂ©thodes: Il s’agissait  d’une Ă©tude de suivi historique rĂ©alisĂ©e aux Cliniques Universitaires de Kinshasa entre mars 2020 et janvier 2021. Le test de χ² a permis la  comparaison des proportions, et la la survie a Ă©tĂ© Ă©tudiĂ©e par la mĂ©thode de Kaplan Meier. L’identification dess prĂ©dicteurs indĂ©pendants de la  mortalitĂ© a Ă©tĂ© dĂ©terminĂ©e par la rĂ©gression de Cox. RĂ©sultats: Des 411 patients enrĂ´lĂ©s, ceux de la 2ème vague Ă©taient beaucoup plus âgĂ©s ((58,1 ±15,7 vs 52,4 ±17,5 ; p=0,026). La 1ère vague a Ă©tĂ©  plus meurtrière que la seconde (p=0,009). La survie Ă©tait plus rĂ©duite dans la première vague par rapport Ă  la seconde. Les facteurs prĂ©dictifs de  mortalitĂ© prĂ©sents Ă  la fois dans la première et la deuxième vague Ă©taient la dĂ©tresse respiratoire et le stade COVID-19 sĂ©vère. Conclusion: La 1ère  vague Ă©tait plus meutrière que la 2ème avec comme prĂ©dicteurs indĂ©pendants la dĂ©tresse respiratoire et le stade COVID-19 sĂ©vère dans les deux  vagues. Le renforcement du système de santĂ© et la sensibilisation sur les mĂ©sures prĂ©ventives dont la vaccination devraient continuer Ă  maintenir  les gains
    corecore